Background
Arthrex challenged the constitutionality of the appointment of Administrative Patent Judges (APJs) who conduct inter partes review proceedings at the PTAB. APJs are appointed by the Secretary of Commerce — not by the President with Senate confirmation — which is the constitutional requirement for “Officers of the United States.” The question was whether APJs are “principal officers” who require Senate confirmation, or “inferior officers” who can be appointed by department heads. If principal officers, their appointment without Senate confirmation violates the Appointments Clause of Article II.
The Federal Circuit had found the APJ appointments unconstitutional and remedied the violation by striking the portion of the AIA that limited the Director’s ability to remove APJs — making APJs removable at will, which the court found would make them inferior officers not requiring Senate confirmation. Both the government and Arthrex appealed.
The Court’s Holding
The Supreme Court held that APJs, as originally structured, exercise authority reserved for principal officers — they issue final decisions on behalf of the United States in IPR proceedings without meaningful review by a principal officer. This violated the Appointments Clause because they were not presidentially appointed with Senate confirmation. However, the Court rejected the Federal Circuit’s remedy (making APJs removable at will) and instead held that the remedy was to give the USPTO Director authority to review final PTAB decisions — making APJ decisions subject to oversight by a Senate-confirmed principal officer, which brings APJs within the “inferior officer” category.
The practical result was that the IPR system remained intact, but PTAB final written decisions could be reviewed and vacated by the USPTO Director — a power the Director had not previously exercised over PTAB decisions on the merits.
Key Takeaways
- PTAB Administrative Patent Judges were unconstitutionally appointed as originally structured — but the remedy was Director review authority rather than invalidating the IPR system or requiring Senate confirmation of APJs.
- The Director of the USPTO now has authority to review and vacate PTAB final written decisions — a significant structural change that gives the executive branch more direct control over IPR outcomes.
- Parties who had PTAB decisions against them before Arthrex could seek remand to allow Director review — though the scope of retroactive relief was contested in subsequent proceedings.
- Arthrex did not disrupt the IPR system structurally, but introduced a new layer of potential Director review that can be invoked by parties and may affect the finality and timeline of PTAB proceedings.
Why It Matters
United States v. Arthrex resolved a constitutional crisis that had threatened to invalidate thousands of PTAB decisions issued in inter partes review proceedings since 2012. By finding the violation but crafting a narrow remedy — Director review authority — the Supreme Court preserved the IPR system while bringing it into constitutional compliance. The decision gave the USPTO Director a new tool for oversight of PTAB decisions, increasing political accountability for patent validity determinations made in the executive branch.
The Arthrex remedy has had practical significance: the USPTO Director has subsequently used the review authority to address PTAB decisions on issues of policy significance, including discretionary denial practices under the Fintiv framework. This has given the Director more active influence over PTAB jurisprudence — blurring the line between adjudication and policy-making at the PTAB in ways that continue to generate controversy among patent practitioners.